Episode
Non-Melanoma Skin Cancer - The Future of Treatment and Dermatological Oncology
- Published
- May 26, 2026
- Duration seconds
- 1621
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-distinctive-dermatologist-6371768/episodes/non-melanoma-skin-cancer-the-future-of-treatment-and-dermatological-oncology/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-distinctive-dermatologist-6371768/non-melanoma-skin-cancer-the-future-of-treatment-and-dermatological-oncology.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Joshua Swindle has seen the many sides of healthcare. From a radiation therapist treating patients to a C-Suite executive for a ground-breaking skin cancer treatment company, his varied career has been united by a central philosophy: It's first and always about the patient. That's why his views on patient choice, the future of skin cancer treatment, and what's next in the field of dermatological oncology are both insightful and important. And they are the topic of this week's edition of The Distinctive Dermatologist. Josh Swindle serves as the Chief Operating Officer of SkinCure Oncology, which is the sponsor of our podcast. However, his message is not specific to GentleCure -- it's important for all who are practitioners and patients seeking the most impactful and effective treatments. Thanks to our sponsor, GentleCure from SkinCure Oncology, for making this program possible.